DelveInsight Business Research, LLP: Minimal Residual Disease Market to Exhibit Growth at a Massive CAGR of 18% During the Study Period (2019-2032), Assesses DelveInsight
The dynamics of the minimal residual disease market are anticipated to change as the future of guided therapies, improvements in the next-generation sequencing detection methods, and the increased
United States Shruti Thakur Dennis Riedl Key Minimal Residual Disease Companies European Scientific Foundation For Laboratory Hemato Oncology Healthcare Asset Prioritization Services
Source: finanznachrichten.de